Abstract

Vaccination with sipuleucel-T produced IgG antibodies to secondary prostatic carcinoma antigens and prolonged survival in some patients, and assaying for antibodies may provide prognostic information and identify new vaccine targets. Additional approaches to improve T-cell responses are needed to improve the clinical efficacy. Clin Cancer Res; 21(16); 3581–3. ©2015 AACR . See related article by GuhaThakurta et al., p. 3619 Received March 11, 2015. Accepted March 15, 2015. ©2015 American Association for Cancer Research.